Gerot Lannach

G.L. Pharma was formed out of a merger of the two pharmaceutical companies Gerot and Lannacher and is looking back at a history of more than 70 years.

We develop, produce and allocate unique brand name products as well as generics for the well-being of people in Austria and abroad. As a supplier to Austria’s healthcare sector, we partner with general practitioners, pharmacists, their patients and pharmaceutical wholesalers.
As an international player, we market our products through our licensees and branch offices to more than 50 countries. Our core competence concentrates on three different business areas:

  • Cardiovascular system
  • Central nervous system
  • Urology, oncology, opioid substitution therapy

Management

We are a private pharmaceutical company offering a product mix of innovative drugs and branded generic drugs.

Martin Bartenstein

CEO

Ilse Bartenstein

CEO

Georg Stark

Managing Director Corporate Strategy - Business Development

top

Company Milestones

1947-48

Foundation of Lannacher Heilmittel in Lannach/Graz and Gerot Pharmazeutika in Vienna

1966

Leopold and Hannelore Bartenstein take over Lannacher Heilmittel

1997

Lannacher Heilmittel acquires Gerot Pharmazeutika

2003

Start of operation in the state-of-the-art solid forms production site Lannach

2009

Lannacher and Gerot merge under the brand Gerot Lannach in G.L. Pharma

2012

Strategic partnership with Valeant Pharmaceuticals in Russia and CIS markets

top

Quick Facts

Markets Distribution of products to more than 50 markets worldwide with own marketing structures in Austria and Eastern Europe
Headcount 715 employees
Revenues € 147M (2017), group revenue including Genericon Pharma € 230M (2017)
Production volume
3.500M defined daily doses
Approved MA 2.034

 

 

top

Company Structure

top

Company Video

Long-standing experience, high quality and quality assurance guarantee pharmaceutical specialities at the highest level.

top